A Systematic Review of Heterogeneity in Outcome Definition and Reporting in Localised Renal Cancer

Ferlay, 2013, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, Eur J Cancer, 49, 1374, 10.1016/j.ejca.2012.12.027 Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660 Sun, 2011, A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis, Eur Urol, 60, 1152, 10.1016/j.eururo.2011.07.064 Rosiello, 2021, Renal cancer: overdiagnosis and overtreatment, World J Urol, 39, 2821, 10.1007/s00345-021-03798-z Martini, 2021, How to select the optimal candidates for renal mass biopsy, Eur Urol Oncol, 4, 506, 10.1016/j.euo.2020.10.001 Ljungberg, 2022, European Association of Urology guidelines on renal cell carcinoma: the 2022 update, Eur Urol, 82, 399, 10.1016/j.eururo.2022.03.006 Beyer, 2021, The current evidence for factors that influence treatment decision making in localized kidney cancer: a mixed methods systematic review, J Urol, 206, 827, 10.1097/JU.0000000000001901 Williamson, 2017, The COMET handbook: version 1.0, Trials, 18, 280, 10.1186/s13063-017-1978-4 MacLennan, 2020, The need for core outcome sets in urological cancer research, Transl Androl Urol, 10, 2832, 10.21037/tau-20-1323 Meregaglia, 2020, A scoping review of core outcome sets and their ‘mapping’ onto real-world data using prostate cancer as a case study, BMC Med Res Methodol, 20, 41, 10.1186/s12874-020-00928-w Violette, 2021, Evidence-based urology: trustworthy guidelines, Eur Urol Focus, 7, 1243, 10.1016/j.euf.2021.10.012 Kirkham, 2010, The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews, BMJ, 340, c365, 10.1136/bmj.c365 Dodd, 2018, A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery, J Clin Epidemiol, 96, 84, 10.1016/j.jclinepi.2017.12.020 MacLennan, 2019, Renal cancer Core Outcome Sets (R-COS) programme encompassing 1) localised renal cell carcinoma (RCC) 2) locally advanced RCC and 3) metastatic RCC, COMET Initiative Beyer, 2022, Updating and integrating core outcome sets for localised, locally advanced, metastatic, and nonmetastatic castration-resistant prostate cancer: an update from the PIONEER Consortium, Eur Urol, 81, 503, 10.1016/j.eururo.2022.01.042 Kirkham, 2016, Core Outcome Set-Standards for Reporting: the COS-STAR statement, PLoS Med, 13, e1002148, 10.1371/journal.pmed.1002148 Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook. Updated October 2013. https://gdt.gradepro.org/app/handbook/handbook.html. Rossi, 2018, Quality of life outcomes in patients with localised renal cancer: a literature review, World J Urol, 36, 1961, 10.1007/s00345-018-2415-3 Rosenblad, 2021, A psychometric evaluation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19) among renal cell carcinoma patients suggesting an alternative two-factor structure, Qual Life Res, 30, 2663, 10.1007/s11136-021-02839-9 Decat Bergerot C, Psutka S, Plimack E, et al. Relevance of items in the FACT Kidney Cancer Symptom Inventory-19 (FKSI-19): results of a patient survey. Presented at the 2022 European International Kidney Cancer Symposium (EIKCS), Antwerp, April 22–24, 2022. Mokkink, 2018, COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures, Qual Life Res, 27, 1171, 10.1007/s11136-017-1765-4 Prinsen, 2018, COSMIN guideline for systematic reviews of patient-reported outcome measures, Qual Life Res, 27, 1147, 10.1007/s11136-018-1798-3